npg

ARTICLE

APC gene hypermethylation and prostate cancer: a systematic review and meta-analysis

Yang Chen[1,5], Jie Li[1,5], Xiaoxiang Yu[2,5], Shuai Li[1], Xuerong Zhang[3], Zengnan Mo[*,1,4] and Yanling Hu[*,1,3]

Prostate cancer (PCa) is a worldwide disease that affects a large number of males. Although prostate-specific antigen (PSA) screening is used, the specificity is limited. This study analyzes the sensitivity and specificity of adenomatous polyposis coli (APC) methylation for PCa detection in body fluids and tissues. Combining search results from PubMed and Embase, 19 studies were included, 5 involving body fluids and 14 involving prostate tissue, with 2344 subjects. In body fluid subgroups, the pooled sensitivity and specificity was 0.53 (95% confidence interval (CI): 0.28–0.78) and 0.92 (95% CI: 0.86–0.95), respectively. From tissue studies, the results presented as 0.84 (95% CI: 0.70–0.92) and 0.91 (95% CI: 0.77–0.97). To confirm the results, we conducted a further analysis by removing studies which introduced high heterogeneity due to the type of cases and controls. The same degree of sensitivity and specificity was presented in two subgroups (urine: sensitivity 0.46, 95% CI: 0.39–0.53; specificity 0.87, 95% CI: 0.64–0.96; tissue: sensitivity 0.87, 95% CI: 0.72–0.94; specificity 0.89, 95% CI: 0.68–0.97). In addition, analysis of the interaction between APC methylation and PCa showed strong association in the whole data set (odds ratio (OR) = 24.91, 95% CI: 12.86–48.24, $I^2 = 72.5\%$). Pooling the same two main subgroups (tissue/fluid) gave a pooled OR of 33.54 (95% CI: 14.88–75.59, $I^2 = 70.7\%$) and 8.20 (95% CI: 2.84–23.74, $I^2 = 64.2\%$), respectively. From this study, the results suggest that APC promoter methylation may be the potential testing for PCa diagnosis and provide a new viewpoint in the treatment of PCa.

INTRODUCTION

Prostate cancer (PCa) is one of the most common cancers in the western world[1] and is said to be the most frequently detected male cancer and the second most frequent cause of male cancer deaths.[2] In 2009, it was suggested that one in six men would be affected, involving 192 280 new cases of PCa and 27 360 PCa-related deaths in the United States.[3] However, significant symptoms can be found in only about half of all diagnosed patients, which indicate the low diagnosis and high mortality rate.[4]

With an increasing rate of morbidity of 3% per year over several decades,[5] reliable methods of diagnosis are needed urgently. In the 1990s, prostate-specific antigen (PSA) testing became widespread,[6] which provided a new approach in the diagnosis of PCa. Disappointingly, although serum PSA is generally used in PCa screening, the poor baseline values and low specificity limits its functions.[7]

DNA methylation of gene promoters may provide the ideal works. There are important advantages of using DNA methylation as cancer biomarkers. In particular, methylated DNA can be detected with a high degree of specificity and sensitivity,[8] which promotes its application to minimal samples from PCa patients. To date, over 50 hypermethylated loci have been identified in PCa.[9,10] Among these loci, adenomatous polyposis coli (APC) is a well-characterized tumor-suppressor gene. The APC gene is located on the long (q) arm of

chromosome 5 between positions 21 and 22, between 112 118 468 and 112 209 532 base pairs (bp). Methylation of the genes is associated with PCa.

The purpose of this study was to conduct a meta-analysis of the sensitivity and specificity of APC methylation on PCa detection in body fluid (blood and urine) and prostate tissues. The results of this article will help to provide a reliable biomarker for the diagnosis and discrimination of PCa. We also determined whether APC methylation was correlated with pathological stage, Gleason score and PSA level among the cases.

MATERIALS AND METHODS
Study selection
We conducted a comprehensive literature search of PubMed and Embase databases using the keywords 'prostate cancer', 'PCa', 'prostate adenocarcinoma', 'APC' and 'adenomatous polyposis coli'. Additional studies were found via the reference lists of the identified articles. The last retrieval was conducted in October 2012. Our inclusion criteria were as follows: (1) measurement of DNA methylation in one of the following samples: blood, plasma, serum, buffy coat, urine, ejaculates, or prostate tissues; (2) a case–control study; and (3) published in English language. Our exclusion criteria were: (1) APC methylation conducted in the cell lines; (2) unavailable raw data on the amount of methylation among cases and controls, respectively (some studies reported specificity and sensitivity without the exact counts); (3) review paper. The selection process for studies included in our review is shown in Figure 1. Our

[1]Center for Genomic and Personalized Medicine, Guangxi Medical University, Nanning, China; [2]Institute of Urology and Nephrology, the People's Liberation Army 303 Hospital of Guangxi, Nanning, China; [3]Medical Research Center, Guangxi Medical University, Nanning, China; [4]Institute of Urology and Nephrology, First Affiliated Hospital of Guangxi Medical University, Nanning, China
[5]These authors contributed equally to this work
*Correspondence: Yanling Hu or Zengnan Mo, Center for Genomic and Personalized Medicine, Guangxi Medical University, NO.22 Shuangyong Road, Nanning, Guangxi Zhuang Autonomous Region 530021, China. Tel: +86 771 5353342; Fax: +86 771 5353342; E-mail: ylhupost@163.com (HY) or zengnanmo@hotmail.com (MZ)
Received 23 August 2012; revised 9 November 2012; accepted 21 November 2012

Figure 1 Flow diagram for the selection of studies.

search strategy and application of the inclusion/exclusion criteria resulted in a total of 19 articles that were included in the systematic review.[11–29] A description of the included studies is given in Tables 1 and 2. The following data were recorded for each study: author's name, year of publication, sample forms, method, 5′-3′ primers (forward and reverse, respectively), amplicon size (bp) and annealing temperature (°C), country, race, cancer clinical classification, PSA, Gleason score, type of cases and controls, type of PCR method and other relevant characteristics of the study population.

Sensitivity and specificity analysis

The normalized index of methylation (NIM) and receiver operator characteristic (ROC) curves were applied in most analyses. NIM was a color-scaled figure in which white represented NIM of zero (no methylation detected) and red defined a NIM of 0.99 (99% of input DNA is methylated). NIM was defined in any given sample to be the ratio of the normalized amount of methylated templates at the promoter of interest to the normalized amount of converted MYOD1 templates (NIM = [(GENE sample)/(GENE SssI)]/[(MYODI sample)/(MYOD SssI)]). Here, GENE sample and GENE SssI were said to be the number of entirely methylated copies of the gene of interest in a given sample. Similar definitions were applied to MYOD1 sample and MYOD1 SssI. In addition, the optimal threshold for methylation was determined on the basis of the area under the ROC curve.[26] Combining the NIM and ROC curve; the numbers of the methylation were recorded.

Before we conducted sensitivity and specificity analyses, the amount of case and control methylation were collected. Among the included studies, two categories were assigned as controls: (1) patients who had negative biopsies but had other diseases including benign prostatic hyperplasia (BPH), and (2) healthy controls. Nevertheless, biopsy-confirmed PCa and high-grade prostatic intraepithelial neoplasia (HGPIN) were treated as cases. Thus, the true-positive (TP) samples were limited to those that had methylation within the exact cases. Meanwhile, in the case samples, the false-positive (FP) ones were indicated to have no methylation. The same definitions was given for true negative (TN) and false negative (FN) in controls. All analyses were conducted with the Midas system in Stata.

Owing to the different types of samples in the eligible studies, we conducted a further analysis to present more robust results on APC methylation as the detection marker. In this analysis, the fluid and tissue subgroups were processed. The types of the samples were described in detail. Among the tissue subgroup, we excluded studies that had other cancer diseases samples (such as lung cancer and bladder cancer) because APC methylation might be also expressed in the different cancers. The analysis of the sensitivity and specificity was then conducted as above. The same processes were applied in the fluid subgroup.

Association analysis

Odds ratios (ORs) with corresponding 95% confidence intervals (CIs) were used to describe the effect of the association between APC methylation and PCa, pathological stage, Gleason score, and PSA levels. The pathological stages were categorized into two subgroups: T1/T2 and T3/T4.[27] For the Gleason score, a score of 7 was used as a cutoff. PSA levels were dichotomized as less or greater than 4 ng/ml. On the basis of individual study ORs, pooled OR was estimated. According to the heterogeneity statistic I^2, a fixed effect or a random-effects model was selected: a fixed effect model was used when $I^2 < 50\%$, otherwise a random-effects model was used. In addition, when the results of the constituent studies differed among themselves, the effects incorporated an estimate of the inter-study variance and therefore provided wider 95% CI. At the same time, the I^2-based Q statistic was used, which describes the weighted sum of the squared difference between the overall effect size and the effect size from each study, to assess heterogeneity ($P < 0.10$ as the standard).[30]

ROC analysis

To assess whether variation in the threshold definition of a positive result produced an association between sensitivity and specificity values across studies, we calculated the summary receiving operating characteristic (S-ROC) curve.[31] The logits of the TP and FP rates were used to estimate the linear regression of the log-OR from each study. Independent analysis of pooled sensitivity and specificity using standard methods for binary data were used when the regression between these quantities was null. All data used a log-odds scale (eg, for specificities, the effect size used was log (Spec/(1-Spec)).[32]

Finally, due to the heterogeneity between studies, we performed the Cochrane Q test of heterogeneity for each analysis (based on deviations of observed log-odds from the common log-odds). The analyses were conducted using Stata 9.0 (Stata Corporation, College Station, TX, USA), and all P-values were two-tailed.

RESULTS

Characteristics

After retrieving search results from the PubMed and Embase databases with the associated keywords, there were 157 and 484 articles retrieved from PubMed and Embase, respectively, on PCa and APC methylation/gene. Among these, we identified 95 relevant studies that described PCa and APC methylation. There were 11 and 29 articles that used fluid (urine, blood or others) samples and tissues, respectively; 55 references were conference abstracts, non-experimental studies or otherwise not available, and were removed, resulting in 40 articles. While reading the full texts, 21 articles were removed. Six could not provide data on the methylation among fluid samples (urine and blood), and[33–38] 15 of the 29 articles using tissues had no raw data (the specific numbers of cases and controls with methylation were unclear, which made it difficult to calculate the data required for sensibility and specificity) or studied other factors such as the *TMPRSS2* gene and urothelial carcinomas.[39–53] Finally, 19 studies met the inclusion criteria and were included.[11–29]

Among these 19 studies, 5 involved body fluid (blood, urine and so on)[11–15] and the remaining 14 articles involved sample tissues.[16–29] Ten studies used quantitative real-time methylation-specific PCR (QMSP) to detect APC methylation,[11,13,14,18,19,21–23,25,26] seven were conducted using the method of methylation-specific PCR (MSP),[12,15,17,20,24,27,29] and two studies used pyrosequencing.[16,28] All

Table 1 Primers used to amplify bisulfite converted DNA at APC promoter regions

Study	Year	Method	Forward	Reverse	Amplicon size (bp)	Annealing temperature (°C)
Hoque *et al*	2005	QMSP	5′-GAACCAAAACGCTCCCCAT-3′	5′-TTATATGTCGGTTACGTGCGTTTATAT-3′	NA	NA
Rogers *et al*	2005	MSP	m5′-TATTGCGGAGTGCGGGTC-3′	m5′-TCGACGAACTCCCGACGA-3′	98	60
			u5′-GTGTTTTATTGTGGAGTGTGGGTT-3′	u5′-CCAATCAACAAACTCCCAACAA-3′	108	62
Rouprêt *et al*	2007	QMSP	5′-GAACCAAAACGCTCCCCAT-3′	5′-TTATATGTCGGTTACGTGCGTTTATAT-3′	NA	NA
Rouprêt *et al*	2008	QMSP	5′-GAACCAAAACGCTCCCCAT-3′	5′-TTATATGTCGGTTACGTGCGTTTATAT-3′	NA	NA
Vener *et al*	2008	MSP	NA	NA	NA	NA
Yoon *et al*	2012	Pyrosequencing	First step: 5′-GGTAAGGGGTTAGGGT TAGGTAG-3′	First step: 5′-ACAACACCTCCATTC TATCT-3′	240	59
			Second step: 5′-GGTAAGGGGTTAGGGTTAGG-TAG-3′	Second step: 5′-Biotin-ACTACACCA ATACAA CCACATATC-3′	200	56
Kang *et al*	2004	MSP	m5′-TATTGCGGAGTGCGGGTC-3′	m5′-TCGACGAACTCCCGACGA-3′	98	55
			u5′-GTGTTTTATTGTGGAGTGTGGGTT-3′	u5′-CCAATCAACAAACTCCCAACAA-3′	108	60
Bastian *et al*	2007	QMSP	5′-TTATATGTCGGTTACGTGCGTTTATAT-3′	5′-GAACCAAAACGCTCCCCAT-3′	NA	NA
Ellinger *et al*	2008	QMSP	5′-GAGGGTATATTTTCGAGGGGTAC-3′	5′-CGACTCTACTCAACATTTAAAAACG-3	NA	62
Maruyama *et al*	2002	MSP	m5′-TATTGCGGAGTGCGGGTC-3′	m5′-TCGACGAACTCCCGACGA-3′	NA	64
			u5′-GTGTTTTATTGTGGAGTGTGGGTT-3′	u5′-CCAATCAACAAACTCCCAACAA-3′	NA	62
Jerónimo *et al*	2004	QMSP	5′-GAACCAAAACGCTCCCCAT-3′	5′-TTATATGTCGGTTACGTGCGTTTATAT-3′	NA	NA
Tokumaru *et al*	2004	QMSP	5′-GAACCAAAACGCTCCCCAT-3′	5′-TTATATGTCGGTTACGTGCGTTTATAT-3′	NA	NA
Bastian *et al*	2005	QMSP	m5′-GAGGGTATATTTTCGAGGGGTAC-3′	m5′-AATAAAAAACGCCCTAATCCG-3′	NA	NA
			u5′-GAGGGTATATTTTTGAGGGGTATG-3′	u5′-AATAAAAAACACCCTAATCCACA-3′		
Enokida *et al*	2005	MSP/USP	m5′-TATTGCGGAGTGCGGGTC-3′	m5′-TCGACGAACTCCCGACGA-3′	NA	NA
			u5′-GTGT-TTTATTGTGGAGTGTGGGTT-3′	u5′-CCAATCAACAAAC-TCCCAACAA-3′		
Henrique *et al*	2006	QMSP	5′-GAACCAAAACGCTCCCCAT-3′	5′-TTATATGTCGGTTACGTGCGTTTATAT-3′	NA	NA
Yegnasubramanian *et al*	2004	QMSP	5′-TTATATGTCGGTTACGTGCGTTTATAT-3′	5′-GAACCAAAACGCTCCCCAT-3′	NA	NA
Cho NY *et al*	2007	MSP	5′-TATTGCGGAGTGCGGGTC-3′	5′-TCGACGAACTCCCGACGA-3′	NA	NA
Vasiljević *et al*	2011	Pyrosequencing	NA	NA	NA	NA
Trock *et al*	2011	MSP/USP	Scorpion probe (5′-3′) GCCGGCGGGTTTTCGACGGGCC GGC-BHQ-HEG-CGAACCAAAACGCTCCCCA	Primer (5′-3′) GTCGGTTACGTGCGTTTATATTTAG	NA	NA

Abbreviations: APC, adenomatous polyposis coli; MSP, methylation-specific PCR; NA, not applicable; QMSP, quantitative real-time methylation-specific PCR.

cases were of PCa or HGPIN and were hospitalized, while controls were limited to be BPH, healthy subjects or those who had genitourinary cancer (bladder carcinoma) with a healthy prostate. In regard to the type of cases, 14 studies were PCa,[11–16,18–20,23,24,27–29] and five were a mixture of PCa, HGPIN and metastasis or other cancer tissues.[17,21,22,25,26] Among the controls, eight studies were normal, biopsy negative, or non-tumor[12–15,17,25,26,29] nine were BPH,[16,18–21,23,24,27,28] and two were a combination of BPH, normal subjects and bladder carcinoma.[11,22] In addition, 14 were Caucasian,[11–15,18–23,25,26,29] four were Asian[16,17,24,27] and one involved mixed races from different continents[28] who came from United States, United Kingdom, Portugal, Germany, Korea, Japan, France, and China.

Specificity and sensitivity of APC promoter methylation using different types of samples

All the results are shown in Table 3. The pooled specificity for all included studies was 0.91 (95% CI: 0.82–0.95), and the pooled sensitivity was 0.78 (95% CI: 0.63–0.88). For the traditional biomarker, the sensitivity of PSA varied, but the specificity was generally low at about 20%,[32,54] which suggested that the APC methylation test has a much higher specificity than the PSA test. There was no evidence of publication bias ($P = 0.33$). In addition, we classified all samples into two groups according to specimen type (fluid/tissue). Among the fluid studies (urine/blood), the pooled sensitivity and specificity was 0.53 (95% CI: 0.28–0.78) and 0.92 (95% CI: 0.86–0.95), respectively. For the tissue studies, the pooled sensitivity and specificity was 0.84 (95% CI: 0.70–0.92) and 0.91 (95% CI: 0.77–0.97), respectively. Publication bias results are showed in Table 3. The S-ROC curve is showed in Figure 2.

In the extra analysis of the sensitivity and specificity, among the studies, we excluded those that would likely introduce high heterogeneity due to different types of cases and controls. Finally, one study[13] and four articles[19,20,22,26] in the fluid and tissue subgroups, respectively, with different samples. The pooled specificity (0.90, 95% CI: 0.77–0.96) and pooled sensitivity (0.78, 95% CI: 0.59–0.90) were similar to the previous results. In addition, in the urine subgroup, the sensitivity was lower (0.45, 95% CI: 0.39–0.53) and the specificity was 0.92 (95% CI: 0.84–0.96). The similar results were presented in the tissue subgroups (sensitivity 0.87, 95% CI: 0.72–0.94; specificity 0.89, 95% CI: 0.68–0.97), which suggested a high level of sensitivity and specificity.

Table 2 Parameters of the studies we included

Author	Year	Country	Race	Sample	Methods	Case type	Control type	Case character	Control character	TP	FP	FN	TN
Hoque et al	2005	USA	Caucasian	Urine	QMSP	Pca	BPH/atypical cells/other cancer disease or normal	NA/hospital/−80 °C	NA/hospital/−80 °C	25	4	27	87
Rogers et al	2005	USA	Caucasian	Urine	MSP	Pca	biopsy negative	NA/hospital/NA	NA/hospital/NA	2	1	10	4
Rouprêt et al	2007	France	Caucasian	Urine	QMSP	Pca	Matched males	2005–2006/hospital/−20 °C DNA	NA/NA/−20 °C_DNA	48	2	47	36
Rouprêt et al	2008	UK	Caucasian	Blood	QMSP	Pca/without or with relapse	Normal	2000/hospital/−80 °C	2000/NA/−80 °C	39	2	3	20
Vener et al	2008	USA/European	Caucasian	Urine	MSP	Pca	Biopsy negative	2006–2007/hospital/4 °C	2006–2007/hospital/4 °C	48	52	63	71
Yoon et al	2012	Korea	Asia	Tissue	Pyrosequencing	Pca	BPH	NA/hospital/−80 °C	NA/hospital/−80 °C	86	2	11	50
Kang et al	2004	Korea	Asia	Tissue	MSP	Pca/HGPIN	Normal	1999–2001/hospital/NA	1999–2001/hospital/NA	26	1	25	19
Bastian et al	2007	Germany	Caucasian	Tissue	QMSP	Pca	BPH	2000–2003/NA/NA	2000–2003/NA/NA	65	0	13	32
Ellinger et al	2008	Germany	Caucasian	Tissue	QMSP	Pca	BPH (after radical cystprostatectomy for bladder cancer or retropubic adenomectomy for BPH)	1995–1999/hospital/NA	1995–1999/hospital/NA	64	8	16	18
Maruyama et al	2002	USA	Caucasian	Tissue	MSP	Pca	BPH/adjacent nonmalignant tissue(PCa7)	1994–2000/hospital/−70 °C	1994–2000/hospital/−70 °C	27	2	74	30
Jerónimo et al	2004	Portugal	Caucasian	Tissue	QMSP	Pca/HGPIN	BPH	NA/hospital/−80 °C	NA/hospital/−80 °C	118	26	0	4
Tokumaru et al	2004	USA	Caucasian	Tissue	QMSP	Pca/bladder carcinoma	Nontumor/bladder carcinoma	2001–2002/hospital/−80 °C	2001–2002/hospital/−80 °C	48	0	13	11
Bastian et al	2005	Germany	Caucasian	Tissue	QMSP	Pca	BPH	2000–2003/hospital/NA	2000–2003/hospital/NA	44	1	9	13
Enokida et al	2005	Japan	Asia	Tissue	MSP/USP	Pca	BPH	1997–2003/hospital/NA	1997–2003/hospital/NA	109	6	61	63
Henrique et al	2006	Portugal	Caucasian	Tissue	QMSP	Pca/HGPIN	Normal	NA/hospital/−80 °C	NA/hospital/−80 °C	131	16	27	14
Yegnasubramanian et al	2004	USA	Caucasian	Tissue	QMSP	Pca/metastatic	Normal	1988–1995/hospital/−80 °C	1988–1995/hospital/−80 °C	66	1	7	24
Cho et al	2007	Korea	Asia	Tissue	MSP	Pca	BPH	1999–2004/hospital/NA	1999–2004/hospital/NA	117	2	62	28
Vasiljević et al	2011	London/China	Mix	Tissue	Pyrosequencing	Pca	BPH	1996–2008/hospital/NA	1996–2008/hospital/NA	46	0	2	29
Trock et al	2011	USA	Caucasian	Tissue	MSP/USP	Pca	Nontumor	NA/hospital/NA	NA/hospital/NA	20	26	1	39

Abbreviations: BPH, benign prostate hyperplasia; BS, bisulphite genomic sequencing; FN, false negative; FP, false positive; HGPIN, high-grade prostatic intraepithelial neoplasia; MSP, methylation-specific PCR; NA, not applicable; Pca, Prostate cancer; QMSP, quantitative real-time methylation-specific PCR; TN, true negative; TP, true positive.
Case and control character: collection years/source of the samples/store temperature.

Table 3 Specificity and sensitivity of APC promoter methylation in all studies and in studies using different types of samples

Number of studies	Specimen type	Methods	Pooled sensitivity	95% CI	Pooled specificity	95% CI	P-value for heterogeneity	P-value for publication bias
5	Urine/blood	QMSP/MSP	0.53	0.28–0.78	0.92	0.86–0.95	0.00	0.76
14	Tissue	QMSP/MSP/pyrosequencing	0.84	0.70–0.92	0.91	0.77–0.97	0.00	0.56
4[a]	Urine	QMSP/MSP	0.45	0.39–0.53	0.92	0.84–0.96	0.00	0.81
10[a]	Tissue	QMSP/MSP/pyrosequencing	0.87	0.72–0.94	0.89	0.68–0.97	0.00	0.63

Abbreviations: APC, adenomatous polyposis coli; CI, confidence interval; N-MSP, non-quantitative methylation-specific PCR; QMSP, quantitative real-time methylation-specific PCR.
Other methods include quantitative methylation-specific PCR, methylation-sensitive restriction endonuclease-qPCR, and bisulphite genomic sequencing.
[a]Studies were removed on the basis of heterogeneity.[19,24,25,27,31]

Association between APC promoter methylation and pathological stage, Gleason score, and PSA levels in PCa cases

We also conducted an analysis of the relationship between the pathological stage, Gleason score, and PSA levels among PCa cases and APC promoter methylation. Details are shown in Table 4. We found no significant association between groups with the appropriate models except for the pathological stage (OR = 0.42, 95% CI: 0.25–0.70, $I^2 = 0.0\%$). Finally, the association between APC promoter methylation and PCa was conducted and the pooled OR was 24.91 (95% CI: 12.86–48.24, $I^2 = 72.5\%$), with pooled ORs of 33.54 (95% CI: 14.88–75.59, $I^2 = 70.7\%$) and 8.20 (95% CI: 2.84–23.74, $I^2 = 64.2\%$) in the tissue and fluid groups, respectively (Figure 3).

DISCUSSION
Description
Although there were have been many studies about of the sensitivity and specificity of APC promoter methylation in relation to PCa, a summary meta-analysis has not been reported. To confirm the real function of APC promoter methylation in predicting PCa, this study is required. This meta-analysis is based on 19 studies containing a total of 1600 cases and 744 controls. The major finding of this study has demonstrated that APC promoter methylation may be associated with PCa. With the high sensitivity and specificity, it would be an ideal biomarker in diagnosing PCa.

Pooled specificity and sensitivity analysis
With the strong association (OR = 24.91, 95% CI: 12.86 −48.24, $I^2 = 72.5\%$), we conducted the specificity and sensitivity analysis. For all included studies, either in the whole data set (pooled specificity 0.90, 95% CI: 0.80–0.95; pooled sensitivity 0.78, 95% CI: 0.63–0.88) or from subgroup analysis (fluid: specificity 0.92, 95% CI: 0.86–0.95; sensitivity 0.53, 95% CI: 0.28–0.78; tissue: specificity 0.91, 95% CI: 0.77–0.97; sensitivity 0.84, 95% CI: 0.70–0.92), the specificity and sensitivity of the test seemed to be high as an biomarker, which suggests a greater directive function in diagnosis with the biomarker of APC methylation. However, due to differences between cases and controls between studies, we removed some studies to make the data more homogeneous. These results suggested no major changes, and therefore provide support to our conclusion. As we have proposed above, the PSA test had varying high sensitivity and poor specificity (about 20%). Therefore, according to our results, APC methylation with high specificity may increase the veracity of diagnosis when combined with the PSA test. For sensitivity, only the fluid subgroup was lower than the PSA test. Due to the high pooled specificity, we propose the following: (1) because of the high sensitivity of the PSA test, potential patients would be screened out. Likewise, APC promoter methylation would need to be detected with high specificity among those patients who were positive in the PSA test. If the results

Figure 2 Meta-analysis with the S-ROC curve.

of both tests were elevated among patients, future biopsies may be warranted. In this way, not only would the diagnosis be elevated, but also the weakness of the PSA test would be remedied. (2) For the tissue subgroup, because of the level of sensitivity (0.84/0.87) and specificity (0.91/0.89) in two analyses, we suggest that the APC methylation test might be a better test to distinguish PCa among the tissue. Although the biopsy was the gold standard in diagnosing PCa, there were still some errors when we did not obtain the cancer tissue well. With the high sensitivity and specificity, the APC methylation test could be used to complement the biopsy, which would decrease the rate of FNs. (3) It has been said that methylation genes might help identify new targets in the individual treatment of some diseases,[55] and our study may provide stronger evidence of the potential function of these genes in finding a cure for PCa.

In addition, although in our analysis we did not find any evidence of publication bias, we should not ignore the potential bias that could affect the results. Nevertheless, regardless of the possible bias, we suggest that studies of the function of methylation in identifying and curing the cancers cannot be neglected.

Limitations
The present study has several limitations. First, the validation assay of the gene promoter methylation used in each study was different (MSP/QMSP/other). In addition, primers selected from different

Table 4 APC promoter methylation in relation to pathological stage, Gleason score, and PSA levels among prostate cases

Clinicopathology	Category	Hypermethylation frequency (%)	OR (95% CIs)	Heterogeneity test (I^2, P-value)	Publication bias test (P-value)
Gleason score	GS<7	52.2	0.64 (0.26–1.57)	66.4%, 0.33	0.79
	GS≥7	64.6			
PSA levels	PSA≤4	65.5	1.30 (0.53–3.21)	0.0%, 0.57	0.13
	PSA>4	54.8			
Pathological stage	Stage (I,II)	58.2	0.42 (0.25–0.70)	0.0%, 0.00	0.43
	Stage (III,IV)	74.8			

Abbreviations: APC, adenomatous polyposis coli; CI, confidence interval; OR, odds ratio; PSA, prostate-specific antigen.


Figure 3 Meta-analysis with random effects for the association between APC methylation and the prostate cancer. The name of the first author and year of publication for each study was shown. For the sample type special analysis, two subgroups were shown: fluid and tissue. For each analysis the OR and accompanying 95% CI are revealed to show the association of the APC methylation and the prostate cancer.

regions of the same CpG Island may have different sensitivities and specificities (Table 1). Second, the thresholds identified by the ROC and INM were determined from individual trials, which may lead to different definitions of methylation. Third, the sample collection time varied widely among the studies. Finally, as mentioned above, we analyzed associations between gene methylation and pathological stage, Gleason score, PSA levels, and other factors, thereby decreasing our statistical power due to multiple testing.

CONCLUSION

PCa is a worldwide disease that affects a large number of men and leads to a serious conclusion. To diagnose and interpose this disease early may indicate a good prognosis. Although the PSA test has been applied in disease diagnosis, its poor specificity limits its function. On the basis of the studies available, this meta-analysis has demonstrated that APC methylation might be an ideal biomarker for screening and identifying PCa when combined with the PSA test to decrease the rate

of unnecessary biopsy. However, given the heterogeneity between the studies and insufficient evidence, the real function of APC methylation in disease diagnosis requires further research.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

DISCLAIMER

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

1 Parkin DM, Bray F, Ferlay J *et al*: Global cancer statistics, 2002. *CA Cancer J Clin* 2005; **55**: 174–108.

2 Jemal A, Siegel R, Ward E *et al*: Cancer statistics, 2008. *CA Cancer J Clin* 2008; **58**: 71–96.

3 Jemal A, Siegel R, Ward E *et al*: Cancer statistics, 2009. *CA Cancer J Clin* 2009; **59**: 225–249.

4 Jemal A, Siegel R, Ward E *et al*: Cancer statistics, 2006. *CA Cancer J Clin* 2006; **56**: 106–130.

5 Zaridze DG, Boyle P, Smans M: International trends in prostatic cancer. *Int J Cancer* 1984; **33**: 223–230.

6 Cooner WH, Mosley BR, Rutherford Jr CL *et al*: Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. 1990. *J Urol* 2002; **167**: 966–973.

7 Stamey TA, Caldwell M, McNeal JE *et al*: The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? *J Urol* 2004; **172**: 1297–1301.

8 Eads CA, Danenberg KD, Kawakami K *et al*: MethyLight: a high-throughput assay to measure DNA methylation. *Nucleic Acids Res* 2000; **28**: E32.

9 Cho NY, Kim JH, Moon KC *et al*: Genomic hypomethylation and CpG island hypermethylation in prostatic intraepithelial neoplasm. *Virchows Arch* 2009; **454**: 17–23.

10 Costa VL, Henrique R, Jerónimo C: Epigenetic markers for molecular detection of prostate cancer. *Dis Markers* 2007; **23**: 31–41.

11 Hoque MO, Topaloglu O, Begum S *et al*: Quantitative methylation-specific polymerase chain reaction gene patterns in urine sediment distinguish prostate cancer patients from control subjects. *J Clin Oncol* 2005; **23**: 6569–6575.

12 Rogers CG, Gonzalgo ML, Yan G *et al*: High concordance of gene methylation in post-digital rectal examination and post-biopsy urine samples for prostate cancer detection. *J Urol* 2006; **176**: 2280–2284.

13 Rouprêt M, Hupertan V, Catto JW *et al*: Promoter hypermethylation in circulating blood cells identifies prostate cancer progression. *Int J Cancer* 2008; **122**: 952–956.

14 Rouprêt M, Hupertan V, Yates DR *et al*: Molecular detection of localized prostate cancer using quantitative methylation-specific PCR on urinary cells obtained following prostate massage. *Clin Cancer Res* 2007; **13**: 1720–1725.

15 Vener T, Derecho C, Baden J *et al*: Development of a multiplexed urine assay for prostate cancer diagnosis. *Clin Chem* 2008; **54**: 874–882.

16 Yoon HY, Kim SK, Kim YW *et al*: Combined hypermethylation of APC and GSTP1 as a Molecular marker for prostate cancer: quantitative pyrosequencing analysis. *J Biomol Screen* 2012; **17**: 987–992.

17 Kang GH, Lee S, Lee HJ *et al*: Aberrant CpG island hypermethylation of multiple genes in prostate cancer and prostatic intraepithelial neoplasia. *J Pathol* 2004; **202**: 233–240.

18 Bastian PJ, Ellinger J, Heukamp LC *et al*: Prognostic value of CpG island hypermethylation at PTGS2, RAR-beta, EDNRB, and other gene loci in patients undergoing radical prostatectomy. *Eur Urol* 2007; **51**: 665–674.

19 Ellinger J, Bastian PJ, Jurgan T *et al*: CpG island hypermethylation at multiple gene sites in diagnosis and prognosis of prostate cancer. *Urology* 2008; **71**: 161–167.

20 Maruyama R, Toyooka S, Toyooka KO *et al*: Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features. *Clin Cancer Res* 2002; **8**: 514–519.

21 Jerónimo C, Henrique R, Hoque MO *et al*: A Quantitative promoter methylation profile of prostate cancer. *Clin Cancer Res* 2004; **10**: 8472–8478.

22 Tokumaru Y, Harden SV, Sun DI *et al*: Optimal use of a panel of methylation markers with GSTP1 hypermethylation in the diagnosis of prostate adenocarcinoma. *Clin Cancer Res* 2004; **10**: 5518–5522.

23 Bastian PJ, Ellinger J, Wellmann A *et al*: Diagnostic and prognostic information in prostate cancer with the help of a small set of hypermethylated gene loci. *Clin Cancer Res* 2005; **11**: 4097–4106.

24 Enokida H, Shiina H, Urakami S *et al*: Multigene methylation analysis for detection and staging of prostate cancer. *Clin Cancer Res* 2005; **11**: 6582–6588.

25 Henrique R, Jerónimo C, Teixeira MR *et al*: Epigenetic heterogeneity of high-grade prostatic intraepithelial neoplasia: clues for clonal progression in prostate carcinogenesis. *Mol Cancer Res* 2006; **4**: 1–8.

26 Yegnasubramanian S, Kowalski J, Gonzalgo ML *et al*: Hypermethylation of CpG islands in primary and metastatic human prostate cancer. *Cancer Res* 2004; **64**: 1975–1986.

27 Cho NY, Kim BH, Choi M *et al*: Hypermethylation of CpG island loci and hypomethylation of LINE-1 and Alu repeats in prostate adenocarcinoma and their relationship to clinicopathological features. *J Pathol* 2007; **211**: 269–277.

28 Vasiljević N, Wu K, Brentnall AR *et al*: Absolute quantitation of DNA methylation of 28 candidate genes in prostate cancer using pyrosequencing. *Dis Markers* 2011; **30**: 151–161.

29 Trock BJ, Brotzman MJ, Mangold LA *et al*: Evaluation of GSTP1 and APC methylation as indicators for repeat biopsy in a high-risk cohort of men with negative initial prostate biopsies. *BJU Int* 2012; **110**: 56–62.

30 Lau J, Ioannidis JP, Schmid CH: Quantitative synthesis in systematic reviews. *Ann Intern Med* 1997; **127**: 820–826.

31 Midgette AS, Stukel TA, Littenberg B: A meta-analytic method for summarizing diagnostic test performances: receiver-operating-characteristic-summary point estimates. *Med Decis Making* 1993; **13**: 253–257.

32 Wu T, Giovannucci E, Welge J *et al*: Measurement of GSTP1 promoter methylation in body fluids may complement PSA screening: a meta-analysis. *Br J Cancer* 2011; **105**: 65–73.

33 Schwarzenbach H, Chun FK, Isbarn H *et al*: Genomic profiling of cell-free DNA in blood and bone marrow of prostate cancer patients. *J Cancer Res Clin Oncol* 2011; **137**: 811–819.

34 Okegawa T, Nutahara K, Higashihara E: Association of circulating tumor cells with tumor-related methylated DNA in patients with hormone-refractory prostate cancer. *Int J Urol* 2010; **17**: 466–475.

35 Phé V, Cussenot O, Rouprêt M: Interest of methylated genes as biomarkers in urothelial cell carcinomas of the urinary tract. *BJU Int* 2009; **104**: 896–901.

36 Phé V, Cussenot O, Rouprêt M: Methylated genes as potential biomarkers in prostate cancer. *BJU Int* 2010; **105**: 1364–1370.

37 Baden J, Green G, Painter J *et al*: Multicenter evaluation of an investigational prostate cancer methylation assay. *J Urol* 2009; **182**: 1186–1193.

38 Baden J, Adams S, Astacio T *et al*: Predicting prostate biopsy result in men with prostate specific antigen 2.0 to 10.0 ng/ml using an investigational prostate cancer methylation assay. *J Urol* 2011; **186**: 2101–2106.

39 Florl AR, Steinhoff C, Müller M *et al*: Coordinate hypermethylation at specific genes in prostate carcinoma precedes LINE-1 hypomethylation. *Br J Cancer* 2004; **91**: 985–994.

40 Van Neste L, Bigley J, Toll A *et al*: A tissue biopsy-based epigenetic multiplex PCR assay for prostate cancer detection. *BMC Urol* 2012; **12**: 16.

41 Stewart GD, Van Neste L, Delvenne P *et al*: Clinical utility of an epigenetic assay to detect occult prostate cancer in histopathologically negative biopsies: results of the MATLOC Study. *J Urol* 2012; **S0022-5347**: 04906–3.

42 Richiardi L, Fiano V, Vizzini L *et al*: Promoter methylation in APC, RUNX3, and GSTP1 and mortality in prostate cancer patients. *J Clin Oncol* 2009; **27**: 3161–3168.

43 Padar A, Sathyanarayana UG, Suzuki M *et al*: Inactivation of cyclin D2 gene in prostate cancers by aberrant promoter methylation. *Clin Cancer Res* 2003; **9**: 4730–4734.

44 Costa VL, Henrique R, Ribeiro FR *et al*: Epigenetic regulation of Wnt signaling pathway in urological cancer. *Epigenetics* 2010; **5**: 343–351.

45 Liu L, Kron KJ, Pethe VV *et al*: Association of tissue promoter methylation levels of APC, TGFβ2, HOXD3 and RASSF1A with prostate cancer progression. *Int J Cancer* 2011; **129**: 2454–2462.

46 Steiner I, Jung K, Schatz P *et al*: Gene promoter methylation and its potential relevance in early prostate cancer diagnosis. *Pathobiology* 2010; **77**: 260–266.

47 Troyer DA, Lucia MS, de Bruïne AP *et al*: Prostate cancer detected by methylated gene markers in histopathologically cancer-negative tissues from men with subsequent positive biopsies. *Cancer Epidemiol Biomarkers Prev* 2009; **18**: 2717–2722.

48 Gillio-Tos A, Fiano V, Zugna D *et al*: DNA methyltransferase 3b (DNMT3b), tumor tissue DNA methylation, Gleason score, and prostate cancer mortality: investigating causal relationships. *Cancer Causes Control* 2012; **23**: 1549–1555.

49 Rosenbaum E, Hoque MO, Cohen Y *et al*: Promoter hypermethylation as an independent prognostic factor for relapse in patients with prostate cancer following radical prostatectomy. *Clin Cancer Res* 2005; **11**: 8321–8325.

50 Delgado-Cruzata L, Hruby GW, Gonzalez K *et al*: DNA methylation changes correlate with Gleason score and tumor stage in prostate cancer. *DNA Cell Biol* 2012; **31**: 187–192.

51 Henrique R, Ribeiro FR, Fonseca D *et al*: High promoter methylation levels of APC predict poor prognosis in sextant biopsies from prostate cancer patients. *Clin Cancer Res* 2007; **13**: 6122–6129.

52 Clark JP, Munson KW, Gu JW *et al*: Performance of a single assay for both type III and type VI TMPRSS2:ERG fusions in noninvasive prediction of prostate biopsy outcome. *Clin Chem* 2008; **54**: 2007–2017.

53 Neuhausen A, Florl AR, Grimm MO *et al*: DNA methylation alterations in urothelial carcinoma. *Cancer Biol Ther* 2006; **5**: 993–1001.

54 Catalona WJ: Management of cancer of the prostate. *N Engl J Med* 1994; **331**: 996–1004.

55 Mahoney SE, Yao Z, Keyes CC *et al*: Genome-wide DNA methylation studies suggest distinct DNA methylation patterns in pediatric embryonal and alveolar rhabdomyosarcomas. *Epigenetics* 2012; **7**: 400–408.